Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 111 clinical trials
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared With Carboplatin-Pemetrexed in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

  • 0 views
  • 06 May, 2021
  • 266 locations
HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

This a phase II-III study. In the single-armed phase II period, HX008, a monoclonal antibody targeting PD-1, will be combined with pemetrexed+platinum (Investigators choice of cisplatin or

  • 0 views
  • 17 Feb, 2021
  • 10 locations
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a

liver metastasis
cancer
neutrophil count
osimertinib
carboplatin
  • 0 views
  • 14 Apr, 2021
  • 11 locations
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the …

epidermal growth factor receptor
metastasis
egfr t790m
growth factor
measurable disease
  • 0 views
  • 31 May, 2021
  • 98 locations
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesothelioma. The efficacy (whether the treatment works), safety and tolerability (side effects of treatment) of atezolizumab plus bevacizumab in …

  • 57 views
  • 14 May, 2021
  • 54 locations
Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer

The aims of this trial are to evaluate the efficacy and tolerability of pemetrexed + paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer.

analgesic
carcinoma
NSAID
cervical carcinoma
antineoplastic
  • 12 views
  • 07 Nov, 2020
  • 1 location
Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

This is a Phase Ib study to evaluate the safety and preliminary anti-tumor activity of pembrolizumab in combination with pemetrexed with or without oxaliplatin in patients with chemo-refractory

oxaliplatin
colorectal adenocarcinoma
adenocarcinoma
liver metastasis
platelet count
  • 4 views
  • 20 Apr, 2021
  • 16 locations
Staggered Chemo-Immunotherapy With Durvalumab MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC

This is a Phase II, open label, randomized study of durvalumab in combination with pemetrexed and carboplatin in eligible adult patients with locally advanced or metastatic non-small cell lung

platelet count
pemetrexed
durvalumab
neutrophil count
metastasis
  • 0 views
  • 24 Jan, 2021
  • 1 location
Neoadjuvant IBI308 Bevacizumab Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC

The purpose of this study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and carboplatin followed by surgery to see how well it works in treating patients with unresectable

  • 0 views
  • 22 Jan, 2021
  • 1 location
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Currently the investigators have two different classes of second-line treatment options in recurrent non-small Cell Lung Cancer (NSCLC). In chemotherapy, docetaxel and pemetrexed

epidermal growth factor receptor
neutrophil count
cetuximab
recurrent non-small cell lung cancer
metastasis
  • 9 views
  • 07 Nov, 2020
  • 1 location